Dr. Lal PathLabs Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Dr. Lal PathLabs Ltd filed with BSE on 06 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Dr. Lal PathLabs reported Q4 FY26 revenue of Rs. 703 crore, up 16.6%, and full year FY26 revenue of Rs. 2,763 crore, up 12.2%, driven mainly by sample volume growth. EBITDA margin for the full year was 27.2%, or 28.3% excluding one-time items including a Rs. 30 crore cost related to the new Labour Code. Management discussed the acquisition of Shahbazkers Diagnostic Centre in Mumbai, continued expansion of labs and collection centres, and the launch of the Sovaaka premium wellness concept and a Dubai subsidiary for international expansion.
Numbers mentioned
Revenue: Rs. 703 crore (Q4 FY26)
p. 3
“We achieved revenue of Rs. 703 crore in Q4 FY26 with a growth of 16.6% and Rs. 2,763 crore in FY26 with a growth of 12.2%.”
Shankha Banerjee, page 3 of the filed PDF · View the filing
Revenue: Rs. 2,763 crore (FY26)
p. 5
“Revenue for the full year stands at Rs. 2,763 crore against Rs. 2,461 crore in FY25, a growth of 12.2%, driven by sample volume growth of 12.9% in Q4 and 10.4% in FY26.”
Ved Goel, page 5 of the filed PDF · View the filing
Revenue per patient: Rs. 956 (Q4 FY26)
p. 5
“Revenue per patient for Q4 FY26 is Rs. 956, up by 7.8% compared to Rs. 887 in Q4 FY25.”
Ved Goel, page 5 of the filed PDF · View the filing
Test per patient: 3.21 (Q4 FY26)
p. 5
“Test per patient for Q4 FY26 stood at 3.21 compared to 3.07 in Q4 last year.”
Ved Goel, page 5 of the filed PDF · View the filing
EBITDA: Rs. 187 crore (Q4 FY26)
p. 5
“EBITDA for Q4 FY26 came in at Rs. 187 crore compared to Rs. 169 crore in Q4 FY25, registering a growth of 10.5% with an EBITDA margin of 26.6%.”
Ved Goel, page 5 of the filed PDF · View the filing
EBITDA: Rs. 752 crore (FY26)
p. 5
“The full year EBITDA stood at Rs. 752 crore compared to Rs. 696 crore in FY25, registering a growth of 8.2% with a margin of 27.2%.”
Ved Goel, page 5 of the filed PDF · View the filing
PBT: Rs. 160 crore (Q4 FY26)
p. 5
“PBT for Q4 FY26 came in at Rs. 160 crore compared to Rs. 154 crore in the same period last year with a margin of 22.8%.”
Ved Goel, page 5 of the filed PDF · View the filing
PAT: Rs. 132 crore (Q4 FY26)
p. 5
“PAT for Q4 FY26 came in at Rs. 132 crore compared to last year Rs. 156 crore in Q4 with a PAT margin of 18.8%.”
Ved Goel, page 5 of the filed PDF · View the filing
PAT: Rs. 510 crore (FY26)
p. 5
“Full year PAT stood at Rs. 510 crore against Rs. 492 crore in FY25 with a margin of 18.4%.”
Ved Goel, page 5 of the filed PDF · View the filing
EPS: Rs. 30.2 (FY26)
p. 5
“EPS for the full year is Rs. 30.2 compared to Rs. 29.2 last year.”
Ved Goel, page 5 of the filed PDF · View the filing
Net cash and cash equivalents: Rs. 1,526 crore
p. 5
“We continue to maintain a strong balance sheet with our net cash and cash equivalents standing at Rs. 1,526 crore, providing ample liquidity for future”
Ved Goel, page 5 of the filed PDF · View the filing
Working capital: negative 26 days
p. 6
“Our commitment to operational excellence is reflected in our lean working capital, which is negative by 26 days.”
Ved Goel, page 6 of the filed PDF · View the filing
Final dividend: Rs. 4 per share (FY26)
p. 6
“the Board of Directors have approved the final dividend of 40%, that is Rs. 4 per share, taking the total dividend for the year to Rs. 20.5 per share, that is 280% after adjustment of bonus issue of 1:1 in Q3 FY26.”
Ved Goel, page 6 of the filed PDF · View the filing
Swasthfit contribution to revenue: 27% (FY26)
p. 4
“Our preventive healthcare brand, Swasthfit, contributed 27% to our total revenue in FY26, proving to be a critical lever for B2C growth.”
Shankha Banerjee, page 4 of the filed PDF · View the filing
Patient volume growth: 8.2% (Q4 FY26)
p. 7
“So, this quarter, volume growth has come at 8.2%.”
Shankha Banerjee, page 7 of the filed PDF · View the filing
Annual patient volume growth: 5.3% (FY26)
p. 8
“If you look at the annual number, the patient volume growth is at 5.3%, which is better than 4.2% and we have given, let is say, 12.2% overall annual revenue growth.”
Shankha Banerjee, page 8 of the filed PDF · View the filing
Revenue from Tier 3+ geographies: 39%
p. 9
“you see close to 39% of our revenues is now coming from Tier 3 plus geographies, and we have a realization, which is in front of you.”
Shankha Banerjee, page 9 of the filed PDF · View the filing
B2C contribution: 75% (FY26)
p. 9
“The B2C contribution this year is about 75%.”
Shankha Banerjee, page 9 of the filed PDF · View the filing
Shahbazkers deal size: Rs. 20 crore
p. 15
“Total deal size is about Rs. 20 crore for this asset.”
Ved Goel, page 15 of the filed PDF · View the filing
Shahbazkers revenue: Rs. 6 crore
p. 6
“We have disclosed it is about a Rs. 6 crore kind of turnover, top line.”
Ved Goel, page 6 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — early to mid-teens · FY27
stated firmly by Shankha Banerjee
p. 4
“We are entering FY27 with strong operational momentum, a strengthened digital infrastructure, and a clear pathway towards sustaining early to mid-teens revenue growth.”
Shankha Banerjee, page 4 of the filed PDF · View the filing
EBITDA margin — 27%-28% · FY27
stated firmly by Ved Goel
p. 7
“we are hopeful for next year also, we are looking something similar margin like between 27% to 28%.”
Ved Goel, page 7 of the filed PDF · View the filing
Capex — Rs. 100 crore - Rs. 120 crore · FY27
stated firmly by Ved Goel
p. 9
“Anshul, for capex, I think we are planning to be in the range of Rs. 100 crore - Rs. 120 crore kind of capex for the next year.”
Ved Goel, page 9 of the filed PDF · View the filing
New labs — 12 to 15 labs · FY27
stated firmly by Ved Goel
p. 10
“Next year also, we are looking 12 to 15 labs, another labs.”
Ved Goel, page 10 of the filed PDF · View the filing
Price increase
stated conditionally by Shankha Banerjee
p. 8
“But definitely, if it is there, it is a few quarters away. It is not something which is immediately on the cards.”
Shankha Banerjee, page 8 of the filed PDF · View the filing
Sovaaka expansion — FY27
stated firmly by Shankha Banerjee
p. 11
“But Sovaaka is one center, and there is no plan to add centres in the next financial year.”
Shankha Banerjee, page 11 of the filed PDF · View the filing
Radiology expansion — next 4-5 years
stated as an aspiration by Shankha Banerjee
p. 13
“We have not set any ambitious targets for us on radiology growth in the next 4-5 years, the way you are suggesting.”
Shankha Banerjee, page 13 of the filed PDF · View the filing
International expansion — next 3-5 years
stated as an aspiration by Ved Goel
p. 16
“It is not something immediate, but over a period of, let us suppose, next 3-5 years, we are looking to expand a few of the geographies.”
Ved Goel, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the asset gives access to a micro market where they lack presence and can be scaled with their products and marketing.
Answered by Shankha Banerjee
Asked by Tausif Shaikh: What is the rationale for acquiring Shahbazkers in Mumbai?
p. 6
“So, this is going to add to our portfolio in that market, given that we are looking at really building our presence strongly in Mumbai and the West region.”
Shankha Banerjee, page 6 of the filed PDF · View the filing
Management attributed higher spend to infra upgrades and advertising, and guided margin to remain in the 27-28% range next year.
Answered by Ved Goel
Asked by Amey Chalke: Is the sharp jump in other expenses sustainable and what is the margin outlook for next year?
p. 7
“we are hopeful for next year also, we are looking something similar margin like between 27% to 28%.”
Ved Goel, page 7 of the filed PDF · View the filing
Management said pricing is set by cluster, not city tier, so Tier 3 expansion has not been dilutive.
Answered by Shankha Banerjee
Asked by Anshul Agrawal: Are Tier 3 geographies dilutive to realizations?
p. 9
“So as of now, it has not been dilutive, and we do not believe it is going to be dilutive going forward as well.”
Shankha Banerjee, page 9 of the filed PDF · View the filing
Management said they have sufficient inventory for now but flagged uncertainty beyond a few months.
Answered by Ved Goel
Asked by Bino Pathiparampil: Does the Middle East war or raw material inflation affect reagent supply or cost?
p. 11
“we have ample sufficient inventory for the next 3-4 months, and we have long-term contracts as well.”
Ved Goel, page 11 of the filed PDF · View the filing
Management said volume growth is not driven by GLP-1 and declined to attribute any FY27 growth to it.
Answered by Shankha Banerjee
Asked by Rahul Salvi: Is GLP-1 drug adoption driving incremental patient volumes or test selection?
p. 16
“I would not ascribe any differential impact due to GLP.”
Shankha Banerjee, page 16 of the filed PDF · View the filing
Management described the Dubai entity as part of a multi-year plan to expand on-ground presence including in the Middle East.
Answered by Ved Goel
Asked by Gaurav Tinani: What is the plan for the new Dubai subsidiary and international expansion?
p. 16
“Right now, we have on-ground presence in Nepal and Bangladesh. But we are looking some of the new geography on ground operations, including Middle East.”
Ved Goel, page 16 of the filed PDF · View the filing
Management said the transition is mostly complete and margins in the West region, including Suburban, still have room to improve.
Answered by Ved Goel
Asked by Hafeez Patel: What is the status of Suburban's transition to a franchisee-led collection model and its margin trajectory?
p. 18
“As I said, I mean, margins for West, including Suburban, there are still rooms to improve because, obviously, it is not a onetime activity.”
Ved Goel, page 18 of the filed PDF · View the filing
Risks flagged
Potential supply chain impact from the Middle East war affecting reagent and consumable imports
p. 11
“If this war continues, obviously, there will be some impact may come on our supply chain.”
Ved Goel, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.